Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 1/2018

01-01-2018 | Original Article

Association of genetic variations in RTN4 3′-UTR with risk for clear cell renal cell carcinoma

Authors: Yan Pu, Peng Chen, Bin Zhou, Peng Zhang, Yanyun Wang, Yaping Song, Lin Zhang

Published in: Familial Cancer | Issue 1/2018

Login to get access

Abstract

Nogo proteins play an important role in the apoptosis of cells, especially in tumor cells. The present study was conducted to evaluate whether the TATC (rs71682980) and CAA (rs34917480) insertion/deletion polymorphisms of RTN4 3′-UTR are associated with clear cell renal cell carcinoma (ccRCC). These two polymorphisms were genotyped in 308 ccRCC patients and 466 healthy controls by polymerase chain reaction polyacrylamide gel electrophoresis (PCR-PAGE). Significantly reduced ccRCC risk was observed to be associated with the TATCins/ins genotype carriers (Versus TATCdel/del: adjusted OR 0.53, 95% CI 0.32–0.87, P = 0.022; Versus TATCdel/del−del/ins: adjusted OR 0.57, 95% CI 0.36–0.92, P = 0.017). After performing stratification analysis, the frequency of TATCins/ins genotype was observed to be significantly higher in patients with N0 compared the patients with N1 (P = 0.003). The present study provide evidence for the first time that the TATC insertion/deletion polymorphism in RTN4 3′-UTR may contributes to ccRCC risk in Chinese Han population.
Literature
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249CrossRefPubMed
2.
3.
Yang L, Parkin DM, Ferlay J, Li L, Chen Y (2005) Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomark Prev 14:243–250CrossRef
4.
5.
Decastro GJ, McKiernan JM (2008) Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin N Am 35:581–592CrossRef
6.
Zhang S, Qian J, Cao Q, Li P, Wang M, Wang J, Ju X, Meng X, Lu Q, Shao P et al (2014) A potentially functional polymorphism in the promoter region of miR-34b/c is associated with renal cell cancer risk in a Chinese population. Mutagenesis 29:149–154CrossRefPubMed
7.
Hirata H, Hinoda Y, Nakajima K, Kikuno N, Yamamura S, Kawakami K, Suehiro Y, Tabatabai ZL, Ishii N, Dahiya R (2009) Wnt antagonist gene polymorphisms and renal cancer. Cancer 115:4488–4503CrossRefPubMedPubMedCentral
8.
Basturk B, Yavascaoglu I, Vuruskan H, Goral G, Oktay B, Oral HB (2005) Cytokine gene polymorphisms as potential risk and protective factors in renal cell carcinoma. Cytokine 30:41–45CrossRefPubMed
9.
Sutphin PD, Chan DA, Li JM, Turcotte S, Krieg AJ, Giaccia AJ (2007) Targeting the loss of the von Hippel-Lindau tumor suppressor gene in renal cell carcinoma cells. Cancer Res 67:5896–5905CrossRefPubMed
10.
Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S et al (2002) Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30:406–410CrossRefPubMed
11.
Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner ML, Duray P, Merino M, Choyke P, Pavlovich CP et al (2002) Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer cell 2:157–164CrossRefPubMed
12.
Khoo SK, Giraud S, Kahnoski K, Chen J, Motorna O, Nickolov R, Binet O, Lambert D, Friedel J, Levy R et al (2002) Clinical and genetic studies of Birt-Hogg-Dube syndrome. J Med Genet 39:906–912CrossRefPubMedPubMedCentral
13.
Teng FY, Tang BL (2008) Cell autonomous function of Nogo and reticulons: the emerging story at the endoplasmic reticulum. J Cell Physiol 216:303–308CrossRefPubMed
14.
Lu DY, Mao XH, Zhou YH, Yan XL, Wang WP, Zheng YB, Xiao JJ, Zhang P, Wang JG, Ashwani N et al (2014) RTN4 3′-UTR insertion/deletion polymorphism and susceptibility to non-small cell lung cancer in Chinese Han population. Asian Pac J Cancer Prev 15:5249–5252CrossRefPubMed
15.
Oertle T, Huber C, van der Putten H, Schwab ME (2003) Genomic structure and functional characterisation of the promoters of human and mouse nogo/rtn4. J Mol Biol 325:299–323CrossRefPubMed
16.
Shi S, Zhou B, Wang Y, Chen Y, Zhang K, Wang K, Quan Y, Song Y, Rao L, Zhang L (2012) Genetic variation in RTN4 3′-UTR and susceptibility to cervical squamous cell carcinoma. DNA Cell Biol 31:1088–1094CrossRefPubMed
17.
Zhang K, Bai P, Shi S, Zhou B, Wang Y, Song Y, Rao L, Zhang L (2013) Association of genetic variations in RTN4 3′-UTR with risk of uterine leiomyomas. Pathol Oncol Res 19:475–479CrossRefPubMed
18.
Novak G, Tallerico T (2006) Nogo A, B and C expression in schizophrenia, depression and bipolar frontal cortex, and correlation of Nogo expression with CAA/TATC polymorphism in 3′-UTR. Brain Res 1120:161–171CrossRefPubMed
19.
Sole X, Guino E, Valls J, Iniesta R, Moreno V (2006) SNPStats: a web tool for the analysis of association studies. Bioinformatics 22:1928–1929CrossRefPubMed
20.
De Craene JO, Coleman J, Estrada de Martin P, Pypaert M, Anderson S, Yates JR 3rd, Ferro-Novick S, Novick P (2006) Rtn1p is involved in structuring the cortical endoplasmic reticulum. Mol Biol Cell 17:3009–3020CrossRefPubMedPubMedCentral
21.
Voeltz GK, Prinz WA, Shibata Y, Rist JM, Rapoport TA (2006) A class of membrane proteins shaping the tubular endoplasmic reticulum. Cell 124:573–586CrossRefPubMed
22.
Liu Y, Vidensky S, Ruggiero AM, Maier S, Sitte HH, Rothstein JD (2008) Reticulon RTN2B regulates trafficking and function of neuronal glutamate transporter EAAC1. J Biol Chem 283:6561–6571CrossRefPubMed
23.
Wakana Y, Koyama S, Nakajima K, Hatsuzawa K, Nagahama M, Tani K, Hauri HP, Melancon P, Tagaya M (2005) Reticulon 3 is involved in membrane trafficking between the endoplasmic reticulum and Golgi. Biochem Biophys Res Commun 334:1198–1205CrossRefPubMed
24.
Acevedo L, Yu J, Erdjument-Bromage H, Miao RQ, Kim JE, Fulton D, Tempst P, Strittmatter SM, Sessa WC (2004) A new role for Nogo as a regulator of vascular remodeling. Nat Med 10:382–388CrossRefPubMed
25.
26.
Watari A, Yutsudo M (2003) Multi-functional gene ASY/Nogo/RTN-X/RTN4: apoptosis, tumor suppression, and inhibition of neuronal regeneration. Apoptosis 8:5–9CrossRefPubMed
27.
GrandPre T, Nakamura F, Vartanian T, Strittmatter SM (2000) Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 403:439–444CrossRefPubMed
28.
Inukai T, Inoue A, Kurosawa H, Goi K, Shinjyo T, Ozawa K, Mao M, Inaba T, Look AT (1999) SLUG, a ces-1-related zinc finger transcription factor gene with antiapoptotic activity, is a downstream target of the E2A-HLF oncoprotein. Mol Cell 4:343–352CrossRefPubMed
29.
30.
Xiao W, Zhou S, Xu H, Li H, He G, Liu Y, Qi Y (2013) Nogo-B promotes the epithelial-mesenchymal transition in HeLa cervical cancer cells via Fibulin-5. Oncol Rep 29:109–116CrossRefPubMed
31.
Chen Y, Tang X, Zhang X, Zhuang L (2009) New mutations of Nogo-C in hepatocellular carcinoma. Mol Biol Rep 36:377–380CrossRefPubMed
32.
Marin EP, Moeckel G, Al-Lamki R, Bradley J, Yan Q, Wang T, Wright PL, Yu J, Sessa WC (2010) Identification and regulation of reticulon 4B (Nogo-B) in renal tubular epithelial cells. Am J Pathol 177:2765–2773CrossRefPubMedPubMedCentral
33.
Chen Y, Tang X, Cao X, Chen H, Zhang X (2006) Human Nogo-C overexpression induces HEK293 cell apoptosis via a mechanism that involves JNK-c-Jun pathway. Biochem Biophys Res Commun 348:923–928CrossRefPubMed
34.
Shi D, Li P, Ma L, Zhong D, Chu H, Yan F, Lv Q, Qin C, Wang W, Wang M et al (2012) A genetic variant in pre-miR-27a is associated with a reduced renal cell cancer risk in a Chinese population. PLoS One 7:e46566CrossRefPubMedPubMedCentral
35.
Li Q, Qi B, Oka K, Shimakage M, Yoshioka N, Inoue H, Hakura A, Kodama K, Stanbridge EJ, Yutsudo M (2001) Link of a new type of apoptosis-inducing gene ASY/Nogo-B to human cancer. Oncogene 20:3929–3936CrossRefPubMed
36.
Shimakage M, Inoue N, Ohshima K, Kawahara K, Oka T, Yasui K, Matsumoto K, Inoue H, Watari A, Higashiyama S et al (2006) Down-regulation of ASY/Nogo transcription associated with progression of adult T-cell leukemia/lymphoma. Int J Cancer 119:1648–1653CrossRefPubMed
37.
Pesole G, Liuni S, Grillo G, Licciulli F, Larizza A, Makalowski W, Saccone C (2000) UTRdb and UTRsite: specialized databases of sequences and functional elements of 5′ and 3′ untranslated regions of eukaryotic mRNAs. Nucleic Acids Res 28:193–196CrossRefPubMedPubMedCentral
38.
Zhou B, Rao L, Li Y, Gao L, Li C, Chen Y, Xue H, Liang W, Lv M, Song Y et al (2009) The association between dilated cardiomyopathy and RTN4 3′UTR insertion/deletion polymorphisms. Clin Chim Acta 400:21–24CrossRefPubMed
39.
Chen Y, Zhou B, Li H, Peng Y, Wang Y, Rao L (2011) Analysis of RTN4 3′UTR insertion/deletion polymorphisms in ventricular septal defect in a Chinese Han population. DNA Cell Biol 30:323–327CrossRefPubMed
Metadata
Title
Association of genetic variations in RTN4 3′-UTR with risk for clear cell renal cell carcinoma
Authors
Yan Pu
Peng Chen
Bin Zhou
Peng Zhang
Yanyun Wang
Yaping Song
Lin Zhang
Publication date
01-01-2018
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2018
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-017-0005-y

Other articles of this Issue 1/2018

Familial Cancer 1/2018 Go to the issue

Short Communication

TP53 germline and somatic mutations in a patient with fibrolamellar hepatocellular carcinoma

Original Article

Quality of life following prophylactic gynecological surgery: experiences of female Lynch mutation carriers

Editorial

The importance of a well-structured pancreatic screening program for familial and hereditary pancreatic cancer

Original Article

Development of a high risk pancreatic screening clinic using 3.0 T MRI

Original Article

Constitutional mismatch repair deficiency and Lynch syndrome among consecutive Arab Bedouins with colorectal cancer in Israel

Original Article

A multi-gene panel study in hereditary breast and ovarian cancer in Colombia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits